A Retrospective Study of Surgery and Reirradiation for Recurrent Ependymoma

Thomas E. Merchant, Frederick A. Boop, Larry E. Kun, Robert A. Sanford

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Purpose: To report disease control for patients with recurrent ependymoma (EP) treated with surgery and a second course of radiation therapy (RT2). Patients and Methods: Thirty-eight pediatric patients (median age, 2.7 years) with initially localized EP at the time of definitive RT underwent a second course of RT after local (n = 21), metastatic (n = 13), or combined (n = 4) failure. Reirradiation included radiosurgery (n = 6), focal fractionated reirradiation (n = 13), or craniospinal irradiation (CSI; n = 19). Results: Initial time to failure was 16 months, and median age at second treatment was 4.8 years. Radiosurgery resulted in significant brainstem toxicity and one death (median dose, 18 Gy). Progression-free survival ratio was greater than unity for 4 of 6 patients; there was one long-term survivor. Three of 13 patients treated using focal fractionated reirradiation (median combined dose, 111.6 Gy) experienced metastasis. The CSI was administered to 12 patients with metastatic failure, 3 patients with local failure, and 4 patients with combined failure. The 4-year event-free survival rate was 53% ± 20% for 12 patients with metastatic failure treated with CSI. Failure after CSI was observed in 1 of 3 patients with a history of local failure and 3 of 4 patients with a history of combined failure. Conclusion: Patients with locally recurrent EP experience durable local tumor control, but remain at risk of metastasis. Patients with metastatic EP failure may receive salvage therapy that includes a component of CSI. Durability of disease control and long-term effects from this approach require further follow-up.

Original languageEnglish (US)
Pages (from-to)87-97
Number of pages11
JournalInternational Journal of Radiation Oncology Biology Physics
Volume71
Issue number1
DOIs
StatePublished - May 1 2008

Fingerprint

Ependymoma
surgery
Retrospective Studies
Radiosurgery
metastasis
Re-Irradiation
Disease-Free Survival
Craniospinal Irradiation
histories
Neoplasm Metastasis
long term effects
Salvage Therapy
dosage
durability
death
progressions
toxicity
Brain Stem
Survivors
unity

Keywords

  • CNS neoplasms
  • Ependymoma
  • Pediatrics
  • Radiotherapy
  • Re-treatment
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

A Retrospective Study of Surgery and Reirradiation for Recurrent Ependymoma. / Merchant, Thomas E.; Boop, Frederick A.; Kun, Larry E.; Sanford, Robert A.

In: International Journal of Radiation Oncology Biology Physics, Vol. 71, No. 1, 01.05.2008, p. 87-97.

Research output: Contribution to journalArticle

Merchant, Thomas E. ; Boop, Frederick A. ; Kun, Larry E. ; Sanford, Robert A. / A Retrospective Study of Surgery and Reirradiation for Recurrent Ependymoma. In: International Journal of Radiation Oncology Biology Physics. 2008 ; Vol. 71, No. 1. pp. 87-97.
@article{e0ad3edad85f4a438d903e86faf8b84e,
title = "A Retrospective Study of Surgery and Reirradiation for Recurrent Ependymoma",
abstract = "Purpose: To report disease control for patients with recurrent ependymoma (EP) treated with surgery and a second course of radiation therapy (RT2). Patients and Methods: Thirty-eight pediatric patients (median age, 2.7 years) with initially localized EP at the time of definitive RT underwent a second course of RT after local (n = 21), metastatic (n = 13), or combined (n = 4) failure. Reirradiation included radiosurgery (n = 6), focal fractionated reirradiation (n = 13), or craniospinal irradiation (CSI; n = 19). Results: Initial time to failure was 16 months, and median age at second treatment was 4.8 years. Radiosurgery resulted in significant brainstem toxicity and one death (median dose, 18 Gy). Progression-free survival ratio was greater than unity for 4 of 6 patients; there was one long-term survivor. Three of 13 patients treated using focal fractionated reirradiation (median combined dose, 111.6 Gy) experienced metastasis. The CSI was administered to 12 patients with metastatic failure, 3 patients with local failure, and 4 patients with combined failure. The 4-year event-free survival rate was 53{\%} ± 20{\%} for 12 patients with metastatic failure treated with CSI. Failure after CSI was observed in 1 of 3 patients with a history of local failure and 3 of 4 patients with a history of combined failure. Conclusion: Patients with locally recurrent EP experience durable local tumor control, but remain at risk of metastasis. Patients with metastatic EP failure may receive salvage therapy that includes a component of CSI. Durability of disease control and long-term effects from this approach require further follow-up.",
keywords = "CNS neoplasms, Ependymoma, Pediatrics, Radiotherapy, Re-treatment, Toxicity",
author = "Merchant, {Thomas E.} and Boop, {Frederick A.} and Kun, {Larry E.} and Sanford, {Robert A.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1016/j.ijrobp.2007.09.037",
language = "English (US)",
volume = "71",
pages = "87--97",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - A Retrospective Study of Surgery and Reirradiation for Recurrent Ependymoma

AU - Merchant, Thomas E.

AU - Boop, Frederick A.

AU - Kun, Larry E.

AU - Sanford, Robert A.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Purpose: To report disease control for patients with recurrent ependymoma (EP) treated with surgery and a second course of radiation therapy (RT2). Patients and Methods: Thirty-eight pediatric patients (median age, 2.7 years) with initially localized EP at the time of definitive RT underwent a second course of RT after local (n = 21), metastatic (n = 13), or combined (n = 4) failure. Reirradiation included radiosurgery (n = 6), focal fractionated reirradiation (n = 13), or craniospinal irradiation (CSI; n = 19). Results: Initial time to failure was 16 months, and median age at second treatment was 4.8 years. Radiosurgery resulted in significant brainstem toxicity and one death (median dose, 18 Gy). Progression-free survival ratio was greater than unity for 4 of 6 patients; there was one long-term survivor. Three of 13 patients treated using focal fractionated reirradiation (median combined dose, 111.6 Gy) experienced metastasis. The CSI was administered to 12 patients with metastatic failure, 3 patients with local failure, and 4 patients with combined failure. The 4-year event-free survival rate was 53% ± 20% for 12 patients with metastatic failure treated with CSI. Failure after CSI was observed in 1 of 3 patients with a history of local failure and 3 of 4 patients with a history of combined failure. Conclusion: Patients with locally recurrent EP experience durable local tumor control, but remain at risk of metastasis. Patients with metastatic EP failure may receive salvage therapy that includes a component of CSI. Durability of disease control and long-term effects from this approach require further follow-up.

AB - Purpose: To report disease control for patients with recurrent ependymoma (EP) treated with surgery and a second course of radiation therapy (RT2). Patients and Methods: Thirty-eight pediatric patients (median age, 2.7 years) with initially localized EP at the time of definitive RT underwent a second course of RT after local (n = 21), metastatic (n = 13), or combined (n = 4) failure. Reirradiation included radiosurgery (n = 6), focal fractionated reirradiation (n = 13), or craniospinal irradiation (CSI; n = 19). Results: Initial time to failure was 16 months, and median age at second treatment was 4.8 years. Radiosurgery resulted in significant brainstem toxicity and one death (median dose, 18 Gy). Progression-free survival ratio was greater than unity for 4 of 6 patients; there was one long-term survivor. Three of 13 patients treated using focal fractionated reirradiation (median combined dose, 111.6 Gy) experienced metastasis. The CSI was administered to 12 patients with metastatic failure, 3 patients with local failure, and 4 patients with combined failure. The 4-year event-free survival rate was 53% ± 20% for 12 patients with metastatic failure treated with CSI. Failure after CSI was observed in 1 of 3 patients with a history of local failure and 3 of 4 patients with a history of combined failure. Conclusion: Patients with locally recurrent EP experience durable local tumor control, but remain at risk of metastasis. Patients with metastatic EP failure may receive salvage therapy that includes a component of CSI. Durability of disease control and long-term effects from this approach require further follow-up.

KW - CNS neoplasms

KW - Ependymoma

KW - Pediatrics

KW - Radiotherapy

KW - Re-treatment

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=41749118317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41749118317&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2007.09.037

DO - 10.1016/j.ijrobp.2007.09.037

M3 - Article

C2 - 18406885

AN - SCOPUS:41749118317

VL - 71

SP - 87

EP - 97

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -